Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.54 |
| ▸ | CA1 | P00915 | 9/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693485 | 0.84 | CA2 (0.47) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL6679273 | 0.83 | CA2 (0.46) | CA2CA1NAMPT | |
| SCHEMBL6678702 | 0.81 | CA2 (0.50) | CA2CA1CA12CA9NQO2 | |
| SCHEMBL6676358 | 0.81 | CA2 (0.44) | CA2CA1CA12CA9KDM4E | |
| SCHEMBL8003356 | 0.79 | CA2 (0.48) | CA2CA1CA12CA9NQO2 | |
| Hydrochloric Acid SCHEMBL6681267 | 0.78 | HTR6 (0.48) | CA2CA1RAB9ACA12CA9 | |
| SCHEMBL6803966 | 0.78 | RAB9A (0.44) | CA2CA1RAB9ACA12CA9 | |
| SCHEMBL6680449 | 0.78 | KDM4E (0.39) | CA2RAB9AKDM4E | |
| SCHEMBL1185780 | 0.78 | CA2 (0.82) | CA2CA1CA12CA9 | |
| SCHEMBL6675966 | 0.77 | CA1 (0.54) | CA2CA1CA12CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | CA2 696/4885CA1 2450/4885RAB9A 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.